The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

Clinical Science

Volumn 109, Issue 3, 2005, Pages 227-241

  Takahashi, Hiroyuki ^a,b   Shibuya, Masabumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Inflammation; Signal transduction; Tumour; Vascular endothelial growth factor (VEGF); Vascular permeability

Indexed keywords

APTAMER; BEVACIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROURACIL; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPILIN 1; NEUROPILIN 2; NITRIC OXIDE; PAXILLIN; PEGAPTANIB; PLACENTAL GROWTH FACTOR; PROTEIN P53; SNAKE VENOM; THYROTROPIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER; CARCINOGENESIS; COLORECTAL CANCER; HUMAN; INFLAMMATION; ISCHEMIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA SPLICING; SOLID TUMOR; STROKE; SURVIVAL;

ANIMALS; CAPILLARY PERMEABILITY; HUMANS; INFLAMMATION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 25144511910     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040370     Document Type: Review

References (167)

1. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309
2. Keck, P. J., Hauser, S. D., Krivi, G. et al. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312
3. Shibuya, M., Yamaguchi, S., Yamane, A. et al. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene 5, 519-524
4. Matthews, W., Jordan, C. T., Gavin, M., Jenkins, N. A., Copeland, N. G. and Lemischka, I. R. (1991) A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. U.S.A. 88, 9026-9030
5. Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L. and Shows, T. B. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-1683
6. Connolly, D. T., Heuvelman, D. M., Nelson, R. et al. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 1470-1478
7. Ferrara, N. and Henzel, W. J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858
8. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985
9. Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C. and de Vos, A. M. (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. U.S.A. 94, 7192-7197
10. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806-1814
11. Tischer, E., Mitchell, R., Hartman, T. et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954
12. Vincenti, V., Cassano, C., Rocchi, M. and Persico, G. (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93, 1493-1495
13. Lange, T., Guttmann-Raviv, N., Baruch, L., Machluf, M. and Neufeld, G. (2003) VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J. Biol. Chem. 278, 17164-17169
14. Bates, D. O. and Harper, S. J. (2002) Regulation of vascular permeability by vascular endothelial growth factors. Vascul. Pharmacol. 39, 225-237
15. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822-7835
16. Ferrara, N. and Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25
17. Melter, M., Reinders, M. E., Sho, M. et al. (2000) Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96, 3801-3808
18. Freeman, M. R., Schneck, F. X., Gagnon, M. L. et al. (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55, 4140-4145
19. Plouet, J., Moro, F., Bertagnolli, S. et al. (1997) Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 272, 13390-13396
20. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. and Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745
21. Gluzman-Poltorak, Z., Cohen, T., Herzog, Y. and Neufeld, G. (2000) Neuropilin-2 and neuropilin-1 are receptors for the 165-ammo acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J. Biol. Chem. 275, 18040-18045
22. Carmeliet, P., Ng, Y. S., Nuyens, D. et al. (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495-502
23. Ruhrberg, C., Gerhardt, H., Golding, M. et al. (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684-2698
24. Stalmans, I., Ng, Y. S., Rohan, R. et al. (2002) Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109, 327-336
25. Maes, C., Stockmans, I., Moermans, K. et al. (2004) Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J. Clin. Invest. 113, 188-199
26. 2 sensing. Science 292, 464-468
27. 2-regulated prolyl hydroxylation. Science 292, 468-472
28. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. and Whitelaw, M. L. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861
29. Gerald, D., Berra, E., Frapart, Y. M. et al. (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794
30. Levy, N. S., Chung, S., Furneaux, H. and Levy, A. P. (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273, 6417-6423
31. Onesto, C., Berra, E., Grepin, R. and Pages, G. (2004) Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J. Biol. Chem. 279, 34217-34226
32. Xie, K., Wei, D., Shi, Q. and Huang, S. (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15, 297-324
33. Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. and Persico, M. G. (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. U.S.A. 88, 9267-9271
34. Persico, M. G., Vincenti, V. and DiPalma, T. (1999) Structure, expression and receptor-binding properties of placental growth factor (PlGF). Curr. Top. Microbiol. Immunol. 237, 31-40
35. Park, J. E., Chen, H. H., Winer, J., Houck, K. A. and Ferrara, N. (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Fit-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654
36. Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M. and Shibuya, M. (1996) Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 7, 213-221
37. Maglione, D., Guerriero, V., Viglietto, G. et al. (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8, 925-931
38. Cao, Y, Ji, W. R., Qi, P. and Rosin, A. (1997) Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem. Biophys. Res. Commun. 235, 493-498
39. Yang, W., Ahn, H., Hinrichs, M., Torry, R. J. and Torry, D. S. (2003) Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J. Reprod. Immunol. 60, 53-60
40. Iyer, S., Leonidas, D. D., Swaminathan, G. J. et al. (2001) The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J. Biol. Chem. 276, 12153-12161
41. Christinger, H. W., Fuh, G., de Vos, A. M. and Wiesmann, C. (2004) The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 279, 10382-10388
42. Errico, M., Riccioni, T., Iyer, S. et al. (2004) Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J. Biol. Chem. 279, 43929-43939
43. Carmeliet, P., Moons, L., Luttun, A. et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575-583
44. Olofsson, B., Jeltsch, M., Eriksson, U. and Alitalo, K. (1999) Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 10, 528-535
45. Bellomo, D., Headrick, J. P., Silins, G. U. et al. (2000) Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86, E29-E35
46. Aase, K., von Euler, G., Li, X. et al. (2001) Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104, 358-364
47. Mould, A. W., Tonks, I. D., Cahill, M. M. et al. (2003) Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 48, 2660-2669
48. Sun, Y., Jin, K., Childs, J. T., Xie, L., Mao, X. O. and Greenberg, D. A. (2004) Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J. Cereb. Blood Flow Metab. 24, 1146-1152
49. Lohela, M., Saaristo, A., Veikkola, T. and Alitalo, K. (2003) Lymphangiogenic growth factors, receptors and therapies. Tnromb. Haemostasis 90, 167-184
50. McColl, B. K., Baldwin, M. E., Roufail, S. et al. (2003) Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 198, 863-868
51. Jeltsch, M., Kaipainen, A., Joukov, V. et al. (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425
52. Karkkainen, M. J., Haiko, P., Sainio, K. et al. (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5, 74-80
53. Stacker, S. A., Caesar, C., Baldwin, M. E. et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186-191
54. Lyttle, D. J., Fraser, K. M., Fleming, S. B., Mercer, A. A. and Robinson, A. J. (1994) Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68, 84-92
55. Wise, L. M., Veikkola, T., Mercer, A. A. et al. (1999) Vascular endothelial growth factor (VEGF)-like protein from orf virus N22 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. U.S.A. 96, 3071-3076
56. Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y. and Shibuya, M. (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273, 31273-31282
57. Wise, L. M., Ueda, N., Dryden, N. H. et al. (2003) Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. J. Biol. Chem. 278, 38004-38014
58. Meyer, M., Clauss, M., Lepple-Wienhues, A. et al. (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363-374
59. Kiba, A., Sagara, H., Hara, T. and Shibuya, M. (2003) VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem. Biophys. Res. Commun. 301, 371-377
60. Junqueira de Azevedo, I. L., Farsky, S. H., Oliveira, M. L. and Ho, P. L. (2001) Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. J. Biol. Chem. 276, 39836-39842
61. Takahashi, H., Hattori, S., Iwamatsu, A., Takizawa, H. and Shibuya, M. (2004) A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J. Biol. Chem. 279, 46304-46314
62. Komori, Y., Nikai, T., Taniguchi, K., Masuda, K. and Sugihara, H. (1999) Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper). Biochemistry 38, 11796-11803
63. Gasmi, A., Bourcier, C., Aloui, Z. et al. (2002) Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. J. Biol. Chem. 277, 29992-29998
64. Yamazaki, Y., Takani, K., Atoda, H. and Morita, T. (2003) Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J. Biol. Chem. 278, 51985-51988
65. Sawano, A., Iwai, S., Sakurai, Y. et al. (2001) Fit-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97, 785-791
66. + stem cells from bone-marrow microenvironment. Nat. Med. 8, 841-849
67. Wiesmann, C., Fuh, G., Christinger, H. W., Eigenbrot, C., Wells, J. A. and de Vos, A. M. (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704
68. Kanno, S., Oda, N., Abe, M. et al. (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19, 2138-2146
69. Kendall, R. L., Wang, G. and Thomas, K. A. (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328
70. Toi, M., Bando, H., Ogawa, T., Muta, M., Hornig, C. and Weich, H. A. (2002) Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 98, 14-18
71. Scheufler, K. M., Drevs, J., van Velthoven, V. et al. (2003) Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man. J. Cereb. Blood Flow Metab. 23, 99-110
72. Levine, R. J., Maynard, S. E., Qian, C. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. New Engl. J. Med. 350, 672-683
73. Maynard, S. E., Min, J. Y., Merchan, J. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
74. Fuh, G., Li, B., Crowley, C., Cunningham, B. and Wells, J. A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197-11204
75. Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. and Satow, Y. (1995) Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55, 5687-5692
76. Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778
77. Wu, L. W., Mayo, L. D., Dunbar, J. D. et al. (2000) VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J. Biol. Chem. 275, 6059-6062
78. Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. and Prigent, S. A. (2000) The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochem. J. 347, 501-509
79. Holmqvist, K., Cross, M. J., Rolny, C. et al. (2004) The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 279, 22267-22275
80. Nagy, J. A., Vasile, E., Feng, D. et al. (2002) Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497-1506
81. Hong, Y. K., Lange-Asschenfeldt, B., Velasco, P. et al. (2004) VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J. 18, 1111-1113
82. Gerber, H. R, McMurtrey, A., Kowalski, J. et al. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343
83. Fujio, Y. and Walsh, K. (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349-16354
84. Byzova, T. V., Goldman, C. K., Pampori, N. et al. (2000) A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell 6, 851-860
85. Ebos, J. M., Bocci, G., Man, S. et al. (2004) A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res. 2, 315-326
86. Makinen, T., Jussila, L., Veikkola, T. et al. (2001) Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199-205
87. Veikkola, T., Jussila, L., Makinen, T. et al. (2001) Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223-1231
88. Makinen, T., Veikkola, T., Mustjoki, S. et al. (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762-4773
89. Chen, L., Hamrah, P., Cursiefen, C. et al. (2004) Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10, 813-815
90. Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O. and Herzog, Y. (2002) The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12, 13-19
91. Takahashi, T., Fournier, A., Nakamura, F. et al. (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99, 59-69
92. Takahashi, T. and Strittmatter, S. M. (2001) Plexina1 autoinhibition by the plexin sema domain. Neuron 29, 429-439
93. 121. J. Biol. Chem. 276, 25520-25531
94. Soker, S., Miao, H. Q., Nomi, M., Takashima, S. and Klagsbrun, M. (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85, 357-368
95. Kitsukawa, T., Shimono, A., Kawakami, A., Kondoh, H. and Fujisawa, H. (1995) Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121, 4309-4318
96. Kawasaki, T., Kitsukawa, T., Bekku, Y. et al. (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126, 4895-4902
97. Yuan, L., Moyon, D., Pardanaud, L. et al. (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129, 4797-4806
98. Carmeliet, P., Ferreira, V., Breier, G. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (London) 380, 435-439
99. Ferrara, N., Carver-Moore, K., Chen, H. et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (London) 380, 439-442
100. Miquerol, L., Langille, B. L. and Nagy, A. (2000) Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127, 3941-3946
101. Fong, G. H., Rossant, J., Gertsenstein, M. and Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (London) 376, 66-70
102. Shalaby, F., Rossant, J., Yamaguchi, T. P. et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (London) 376, 62-66
103. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. and Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 95, 9349-9354
104. Takahashi, T., Ueno, H. and Shibuya, M. (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221-2230
105. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. (2005) Essential role of Flk-1 (vascular endothelial growth factor receptor-2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 102, 1076-1081
106. Lamalice, L., Houle, F., Jourdan, G. and Huot, J. (2004) Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23, 434-445
107. Vinals, F., Chambard, J. C. and Pouyssegur, J. (1999) p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J. Biol. Chem. 274, 26776-26782
108. Yamazaki, T., Akada, T., Niizeki, O., Suzuki, T., Miyashita, H. and Sato, Y. (2004) Puromycin-insensitive leucyl-specific aminopeptidase (PILSAP) binds and catalyzes PDK1, allowing VEGF-stimulated activation of S6K for endothelial cell proliferation and angiogenesis. Blood 104, 2345-2352
109. Baldanzi, G., Mitola, S., Cutrupi, S. et al. (2004) Activation of diacylglycerol kinase α is required for VEGF-induced angiogenic signaling in vitro. Oncogene 23, 4828-4838
110. Chai, J., Jones, M. K. and Tarnawski, A. S. (2004) Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis. FASEB J. 18, 1264-1266
111. Zhou, R. H., Yao, M., Lee, T. S., Zhu, Y., Martins-Green, M. and Shyy, J. Y. (2004) Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis. Circ. Res. 95, 471-478
112. Yamaoka-Tojo, M., Ushio-Fukai, M., Hilenski, L. et al. (2004) IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ. Res. 95, 276-283
113. Watanabe, K., Hasegawa, Y., Yamashita, H. et al. (2004) Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 114, 898-907
114. Hesser, B. A., Liang, X. H., Camenisch, G. et al. (2004) Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 104, 149-158
115. Minami, T., Horiuchi, K., Miura, M. et al. (2004) Vascular endothelial growth factor- and thrombin-induced termination factor, down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J. Biol. Chem. 279, 50537-50554
116. Luo, J. C., Yamaguchi, S., Shinkai, A., Shitara, K. and Shibuya, M. (1998) Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 58, 2652-2660
117. Zebrowski, B. K., Yano, S., Liu, W. et al. (1999) Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 5, 3364-3368
118. Kevil, C. G., Payne, D. K., Mire, E. and Alexander, J. S. (1998) Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J. Biol. Chem. 273, 15099-15103
119. Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J. and Cheresh, D. A. (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915-924
120. Weis, S., Shintani, S., Weber, A. et al. (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113, 885-894
121. Fukumura, D., Yuan, F., Endo, M. and Jain, R. K. (1997) Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol. 150, 713-725
122. Fukumura, D., Gohongi, T., Kadambi, A. et al. (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U.S.A. 98, 2604-2609
123. Fulton, D., Gratton, J. P., McCabe, T. J. et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (London) 399, 597-601
124. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A. M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (London) 399, 601-605
125. Eriksson, A., Cao, R., Roy, J. et al. (2003) Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation 107, 1532-1538
126. Issbrucker, K., Marti, H. H., Hippenstiel, S. et al. (2003) p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 17, 262-264
127. Fukumura, D., Xavier, R., Sugiura, T. et al. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725
128. Holmgren, L., O'Reilly, M. S. and Folkman, J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149-153
129. Ferrara, N., Hillan, K. J., Gerber, H. P. and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400
130. Hiratsuka, S., Maru, Y., Okada, A., Seiki, M., Noda, T. and Shibuya, M. (2001) Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61, 1207-1213
131. Autiero, M., Waltenberger, J., Communi, D. et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9, 936-943
132. Yoshiji, H., Kuriyama, S., Yoshii, J. et al. (2004) Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39, 1517-1524
133. Christofori, G., Naik, P. and Hanahan, D. (1995) Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol. 9, 1760-1770
134. Inoue, M., Hager, J. H., Ferrara, N., Gerber, H. P. and Hanahan, D. (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 1, 193-202
135. Bergers, G., Brekken, R., McMahon, G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744
136. Weis, S., Cui, J., Barnes, L. and Cheresh, D. (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 167, 223-229
137. Schmitt, M., Horbach, A., Kubitz, R., Frilling, A. and Haussinger, D. (2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J. Hepatol. 41, 274-283
138. Hiratsuka, S., Nakamura, K., Iwai, S. et al. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300
139. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 350, 2335-2342
140. Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L. and Jain, R. K. (1996) During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2, 992-997
141. Kim, I., Moon, S. O., Kim, S. H., Kim, H. J., Koh, Y. S. and Koh, G. Y. (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells. J. Biol. Chem. 276, 7614-7620
142. Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Mantovani, A. and Marme, D. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343
143. Detmar, M., Brown, L. F., Schon, M. P. et al. (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1-6
144. Kunstfeld, R., Hirakawa, S., Hong, Y. K. et al. (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104, 1048-1057
145. Oura, H., Bertoncini, J., Velasco, P., Brown, L. F., Carmeliet, P. and Detmar, M. (2003) A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 101, 560-567
146. Matsumoto, Y., Tanaka, K., Hirata, G. et al. (2002) Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J. Immunol. 168, 5824-5831
147. Luttun, A., Tjwa, M., Moons, L. et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840
148. De Bandt, M., Ben Mahdi, M. H., Ollivier, V. et al. (2003) Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J. Immunol. 171, 4853-4859
149. Lee, Y. C. and Lee, H. K. (2001) Vascular endothelial growth factor in patients with acute asthma. J. Allergy Clin. Immunol. 107, 1106
150. Hoshino, M., Nakamura, Y. and Hamid, Q. A. (2001) Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J. Allergy Clin. Immunol. 107, 1034-1038
151. Lee, C. G., Link, H., Baluk, P. et al. (2004) Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat. Med. 10, 1095-1103
152. Reinders, M. E., Sho, M., Izawa, A. et al. (2003) Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest. 112, 1655-1665
153. Zhao, Q., Egashira, K., Hiasa, K. et al. (2004) Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler., Thromb., Vasc. Biol. 24, 2284-2289
154. Marti, H. J., Bernaudin, M., Bellail, A. et al. (2000) Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156, 965-976
155. van Bruggen, N., Thibodeaux, H., Palmer, J. T. et al. (1999) VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613-1620
156. Paul, R., Zhang, Z. G., Eliceiri, B. P. et al. (2001) Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 7, 222-227
157. Sun, Y., Jin, K., Xie, L. et al. (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 111, 1843-1851
158. Manoonkitiwongsa, P. S., Schultz, R. L., McCreery, D. B., Whitter, E. F. and Lyden, P. D. (2004) Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J. Cereb. Blood Flow Metab. 24, 693-702
159. Campochiaro, P. A. and Hackett, S. F. (2003) Ocular neovascularization: a valuable model system. Oncogene 22, 6537-6548
160. Gragoudas, E. S., Adamis, A. P., Cunningham, Jr, E. T., Feinsod, M. and Guyer, D. R. (2004) Pegaptanib for neovascular age-related macular degeneration. New Engl. J. Med. 351, 2805-2816
161. Oosthuyse, B., Moons, L., Storkebaum, E. et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131-138
162. Lambrechts, D., Storkebaum, E., Morimoto, M. et al. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34, 383-394
163. Azzouz, M., Ralph, G. S., Storkebaum, E. et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (London) 429, 413-417
164. Storkebaum, E., Lambrechts, D., Dewerchin, M. et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8, 85-92
165. LeCouter, J., Moritz, D. R., Li, B. et al. (2003) Angiogenesis- independent endothelial protection of liver: role of VEGFR-1. Science 299, 890-893
166. Dixelius, J., Makinen, T., Wirzenius, M. et al. (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimenzation with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278, 40973-40979
167. Cao, L., Jiao, X., Zuzga, D. S. et al. (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 36, 827-835